{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:07:15Z","timestamp":1786997235184,"version":"build-2736575974"},"reference-count":223,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011377","name":"Glaucoma UK","doi-asserted-by":"publisher","award":["183772"],"award-info":[{"award-number":["183772"]}],"id":[{"id":"10.13039\/100011377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["CL2020-18-009"],"award-info":[{"award-number":["CL2020-18-009"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019418","name":"NIHR Maudsley Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.survophthal.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:44:06Z","timestamp":1744803846000},"page":"900-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the potential of rho kinase inhibitors in ophthalmology: From mechanisms to clinical practice"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-355X","authenticated-orcid":false,"given":"Jit Kai","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananth","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi G.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng Tee","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-5355","authenticated-orcid":false,"given":"Christin","family":"Henein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/09298665113209990057","article-title":"Rho kinase inhibitors and novel ocular drug delivery systems- a revolutionary step towards the treatment of glaucoma","volume":"13","author":"Abbhi","year":"2016","journal-title":"Curr Drug Deliv"},{"issue":"ement 1","key":"10.1016\/j.survophthal.2025.03.008_bib2","article-title":"PSS4 A Cost Effectiveness analysis of latanoprost monotherapy, netarsudil monotherapy and fixed dose combination latanoprost\/netarsudil in management of primary open angle glaucoma in USA","volume":"24","author":"Adjei","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.survophthal.2025.03.008_bib3","unstructured":"Administration USFaD. Rhopressa Information Leaflet 2017 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208254lbl.pdf."},{"key":"10.1016\/j.survophthal.2025.03.008_bib4","unstructured":"Agency EM. Rhokiinsa European Medicines Agency2022 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rhokiinsa."},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bjophthalmol-2018-312244","article-title":"Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial","volume":"103","author":"Ahmadieh","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/JEP.S259297","article-title":"Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma","volume":"13","author":"Al-Humimat","year":"2021","journal-title":"J Exp Pharm"},{"key":"10.1016\/j.survophthal.2025.03.008_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/JEP.S259297","article-title":"Investigational rho kinase inhibitors for the treatment of glaucoma","volume":"13","author":"Al-Humimat","year":"2021","journal-title":"J Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib8","first-page":"978","article-title":"Rho and Rho-kinase (ROCK) signaling in adherens and gap junction assembly in corneal epithelium","volume":"43","author":"Anderson","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.008_bib9","first-page":"1","article-title":"Targeting schlemm's canal in the medical therapy of glaucoma: current and future considerations","author":"Andres-Guerrero","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2025.03.008_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/175163","article-title":"ROCK as a therapeutic target of diabetic retinopathy","volume":"2010","author":"Arita","year":"2010","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/db08-0762","article-title":"Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage","volume":"58","author":"Arita","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.survophthal.2025.03.008_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial","volume":"207","author":"Asrani","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.03.008_bib14","article-title":"Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma","author":"Bahr","year":"2022","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s00125-016-3974-8","article-title":"Diabetic macular oedema: pathophysiology, management challenges and treatment resistance","volume":"59","author":"Bahrami","year":"2016","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/13543776.2019.1670812","article-title":"Rho-kinase inhibitors in the management of glaucoma","volume":"29","author":"Berrino","year":"2019","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nbd.2006.08.008","article-title":"Enhanced survival and regeneration of axotomized retinal neurons by repeated delivery of cell-permeable C3-like Rho antagonists","volume":"25","author":"Bertrand","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib18","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1096\/fj.09-145102","article-title":"RhoA\/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis","volume":"24","author":"Bryan","year":"2010","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543776.2012.649006","article-title":"Novel therapies for glaucoma: A patent review 2007 - 2011","volume":"22","author":"Carta","year":"2012","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/13543784.2013.840288","article-title":"Rho-kinase inhibitors offer a new approach in the treatment of glaucoma","volume":"23","author":"Challa","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.008_bib22","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1167\/iovs.18-25369","article-title":"Constriction of retinal venules to endothelin-1: obligatory roles of ETA receptors, extracellular calcium entry, and rho kinase","volume":"59","author":"Chen","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9735","key":"10.1016\/j.survophthal.2025.03.008_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.008_bib24","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"2020","author":"Clement Freiberg","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib25","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","author":"Clement Freiberg","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2025.03.008_bib26","unstructured":"ClinicalTrials. A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05660447?intr=Netarsudil&page=\u20094&rank=\u200931."},{"key":"10.1016\/j.survophthal.2025.03.008_bib27","unstructured":"ClinicalTrials. A Phase 1\/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (CLARA) 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT06041256?intr=Y-27632&rank=\u20092."},{"key":"10.1016\/j.survophthal.2025.03.008_bib28","unstructured":"ClinicalTrials. A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05795699?intr=Ripasudil&rank=\u20095."},{"key":"10.1016\/j.survophthal.2025.03.008_bib29","unstructured":"ClinicalTrials. A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05826353?intr=Ripasudil&rank=\u20096."},{"key":"10.1016\/j.survophthal.2025.03.008_bib30","unstructured":"ClinicalTrials. A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05528172?intr=Ripasudil&rank=\u20094&tab=table."},{"key":"10.1016\/j.survophthal.2025.03.008_bib31","unstructured":"ClinicalTrials. Descemet Endothelial Thickness Comparison Trial II (DETECT II) 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05275972?intr=Ripasudil&rank=\u20093."},{"key":"10.1016\/j.survophthal.2025.03.008_bib32","unstructured":"ClinicalTrials. Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy 2021 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03249337?intr=Ripasudil&rank=\u20099."},{"key":"10.1016\/j.survophthal.2025.03.008_bib33","unstructured":"ClinicalTrials. Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT04752020?intr=Netarsudil&rank=\u20095."},{"key":"10.1016\/j.survophthal.2025.03.008_bib34","unstructured":"ClinicalTrials. Study to Assess Safety and Tolerability of Multiple Doses of EO2002 2022 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05636579?intr=Ripasudil&rank=\u20092&tab=table."},{"key":"10.1016\/j.survophthal.2025.03.008_bib35","unstructured":"ClinicalTrials. Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT04250207."},{"key":"10.1016\/j.survophthal.2025.03.008_bib36","unstructured":"ClinicalTrials. The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT06048380?intr=Ripasudil&rank=\u20091."},{"key":"10.1016\/j.survophthal.2025.03.008_bib37","unstructured":"ClinicalTrials. Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT06033703?intr=Netarsudil&rank=\u20092."},{"key":"10.1016\/j.survophthal.2025.03.008_bib38","unstructured":"ClinicalTrials.org. A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction (Escalon) 2022 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05309135?intr=Rho-Kinase%20Inhibitor&viewType=Table&rank=\u20095."},{"key":"10.1016\/j.survophthal.2025.03.008_bib39","unstructured":"ClinicalTrials.org. Descemet Endothelial Thickness Comparison Trial I (DETECT I) 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05289661?intr=Rho-Kinase%20Inhibitor&viewType=Table&page=\u20092&rank=\u200913."},{"key":"10.1016\/j.survophthal.2025.03.008_bib40","unstructured":"ClinicalTrials.org. Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy 2018 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03575130?intr=Rho-Kinase%20Inhibitor&viewType=Table&page=\u20092&rank=\u200916."},{"key":"10.1016\/j.survophthal.2025.03.008_bib41","unstructured":"ClinicalTrials.org. Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03813056?intr=Rho-Kinase%20Inhibitor&viewType=Table&page=\u20092&rank=\u200917."},{"key":"10.1016\/j.survophthal.2025.03.008_bib42","doi-asserted-by":"crossref","unstructured":"Copland D.A., Theodoropoulou S., Liu J., Dick A.D. A Perspective of AMD Through the Eyes of Immunology. Invest Ophthalmol Vis Sci. 2018;59(4):AMD83-AMD92.","DOI":"10.1167\/iovs.18-23893"},{"key":"10.1016\/j.survophthal.2025.03.008_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.visres.2017.03.013","article-title":"Muller cells and diabetic retinopathy","volume":"139","author":"Coughlin","year":"2017","journal-title":"Vis Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41588-019-0556-y","article-title":"Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression","volume":"52","author":"Craig","year":"2020","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.5.6.7","article-title":"ROCK inhibition promotes attachment, proliferation, and wound closure in human embryonic stem cell-derived retinal pigmented epithelium","volume":"5","author":"Croze","year":"2016","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.phrs.2007.04.016","article-title":"The role of protein kinase C activation and the vascular complications of diabetes","volume":"55","author":"Das","year":"2007","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/13543776.2017.1272579","article-title":"Rho kinase inhibitors: a patent review (2014-2016)","volume":"27","author":"Defert","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"15","key":"10.1016\/j.survophthal.2025.03.008_bib48","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1523\/JNEUROSCI.22-15-06570.2002","article-title":"Rho signaling pathway targeted to promote spinal cord repair","volume":"22","author":"Dergham","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.survophthal.2025.03.008_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","article-title":"Neurotrophic keratopathy","volume":"66","author":"Dua","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib50","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jcjo.2021.11.009","article-title":"Use of ripasudil for rapid resolution of acute hydrops in keratoconus","volume":"57","author":"Eslami","year":"2022","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib51","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1167\/iovs.04-0201","article-title":"CD-34 expression by cultured human keratocytes is downregulated during myofibroblast differentiation induced by TGF-beta1","volume":"45","author":"Espana","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6916","key":"10.1016\/j.survophthal.2025.03.008_bib52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2025.03.008_bib53","unstructured":"Excellence NIfHaC. Latanoprost\u2013netarsudil for previously treated primary open-angle glaucoma or ocular hypertension 2024 [Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta1009\/chapter\/3-Committee-discussion#clinical-effectiveness\u3009."},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib54","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ajo.2014.01.017","article-title":"Acute corneal hydrops in keratoconus - new perspectives","volume":"157","author":"Fan Gaskin","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0039-6257(05)80042-6","article-title":"Mechanisms of optic nerve damage in primary open angle glaucoma","volume":"39","author":"Fechtner","year":"1994","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib56","article-title":"Corneal endothelial cell dysfunction: etiologies and management","volume":"10","author":"Feizi","year":"2018","journal-title":"Ther Adv Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-022-00389-x","article-title":"Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study","volume":"8","author":"Fekri","year":"2022","journal-title":"Int J Retin Vitr"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib58","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","article-title":"Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential","volume":"59","author":"Feng","year":"2016","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib59","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0042-6989(02)00680-6","article-title":"Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data","volume":"43","author":"Fisher","year":"2003","journal-title":"Vis Res"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib60","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1167\/iovs.07-1580","article-title":"RhoA and its role in synaptic structural plasticity of isolated salamander photoreceptors","volume":"49","author":"Fontainhas","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1167\/iovs.10-5744","article-title":"RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment","volume":"52","author":"Fontainhas","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0161-6420(81)34962-8","article-title":"Treatment of recurrent corneal erosion and corneal edema with topical osmotic colloidal solution","volume":"88","author":"Foulks","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.03.008_bib63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exer.2016.07.001","article-title":"The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts","volume":"149","author":"Futakuchi","year":"2016","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib64","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12886-020-01400-5","article-title":"Ripasudil alleviated the inflammation of RPE cells by targeting the miR-136-5p\/ROCK\/NLRP3 pathway","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/IJG.0000000000001889","article-title":"A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients","volume":"30","author":"Gazzard","year":"2021","journal-title":"J Glaucoma"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib66","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/jnc.12681","article-title":"Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions","volume":"129","author":"Gibson","year":"2014","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.ijg.0000212250.95078.6f","article-title":"Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study","volume":"15","author":"Gieser","year":"2006","journal-title":"J Glaucoma"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/cells12101367","article-title":"The RhoA-ROCK1\/ROCK2 pathway exacerbates inflammatory signaling in immortalized and primary microglia","volume":"12","author":"Glotfelty","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib69","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/IJG.0b013e318241b83c","article-title":"Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma","volume":"21","author":"Goldhagen","year":"2012","journal-title":"J Glaucoma"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.icu.0000156134.38495.0b","article-title":"Blood flow in glaucoma","volume":"16","author":"Grieshaber","year":"2005","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/genes14020272","article-title":"Effect of the Rho-Kinase\/ROCK signaling pathway on cytoskeleton components","volume":"14","author":"Guan","year":"2023","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICU.0000000000000658","article-title":"Improving outcomes in retinal detachment: the potential role of rho-kinase inhibitors","volume":"31","author":"Halasz","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib73","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41598-020-80267-4","article-title":"ROCK inhibition reduces morphological and functional damage to rod synapses after retinal injury","volume":"11","author":"Halasz","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.008_bib74","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"issue":"32","key":"10.1016\/j.survophthal.2025.03.008_bib75","doi-asserted-by":"crossref","first-page":"28917","DOI":"10.1074\/jbc.M504803200","article-title":"Extracellular trafficking of myocilin in human trabecular meshwork cells","volume":"280","author":"Hardy","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10384-007-0487-5","article-title":"Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor","volume":"52","author":"Hata","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100964","article-title":"Photocoagulation for retinal vein occlusion","volume":"85","author":"Hayreh","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib78","first-page":"488","article-title":"Ocular neovascularization with retinal vascular occlusion-III","volume":"90","author":"Hayreh","year":"1983","journal-title":"Incid Ocul neovascularization Retin vein occlusion Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice","volume":"134","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib80","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1167\/iovs.09-4391","article-title":"Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles","volume":"51","author":"Hein","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jphs.2018.06.010","article-title":"Effects of ripasudil, a ROCK inhibitor, on retinal edema and nonperfusion area in a retinal vein occlusion murine model","volume":"137","author":"Hida","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00417-007-0666-6","article-title":"Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia","volume":"246","author":"Hirata","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib83","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1073\/pnas.0308525100","article-title":"Rho activity critically and selectively regulates endothelial cell organization during angiogenesis","volume":"101","author":"Hoang","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib84","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1167\/iovs.14-15681","article-title":"The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration","volume":"56","author":"Hollanders","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","article-title":"Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma","volume":"62","author":"Honjo","year":"2018","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.008_bib86","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1167\/iovs.07-0878","article-title":"Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery","volume":"48","author":"Honjo","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib87","doi-asserted-by":"crossref","first-page":"399","DOI":"10.31925\/farmacia.2021.3.2","article-title":"Rho-kinase inhibitors - a new broad-spectrum treatment in ophthalmic diseases. A review","volume":"69","author":"Iancu","year":"2021","journal-title":"Farmacia"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cbf.3382","article-title":"An in vitro study of scarring formation mediated by human Tenon fibroblasts: effect of Y-27632, a Rho kinase inhibitor","volume":"37","author":"Ibrahim","year":"2019","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib89","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cbf.3382","article-title":"An in vitro study of scarring formation mediated by human Tenon fibroblasts: effect of Y-27632, a Rho kinase inhibitor","volume":"37","author":"Ibrahim","year":"2019","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib90","first-page":"93","article-title":"Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure","volume":"38","author":"Inoue","year":"2018","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib91","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.exer.2006.10.017","article-title":"Inhibition of RhoA\/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells","volume":"84","author":"Itoh","year":"2007","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1017\/S0952523803202017","article-title":"Involvement of glutamate in ischemic neurodegeneration in isolated retina","volume":"20","author":"Izumi","year":"2003","journal-title":"Vis Neurosci"},{"key":"10.1016\/j.survophthal.2025.03.008_bib93","unstructured":"Jasien J. A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma (ROCK - CACG) Clinicaltrials.gov2015 [Available from: \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT02152774?term=rho+kinase+inhibitor&cond=Ocular+Hypertension&draw=\u20092&rank=\u20092\u3009."},{"key":"10.1016\/j.survophthal.2025.03.008_bib94","unstructured":"Jasien J. A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt Clinicaltrials.gov2015 [Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02173223?term=rho+kinase+inhibitor&cond=Ocular+Hypertension&draw=\u20092&rank=\u20093."},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib95","first-page":"1670","article-title":"Modulation of outflow resistance by the pores of the inner wall endothelium","volume":"33","author":"Johnson","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.exer.2011.08.014","article-title":"Proliferative capacity of corneal endothelial cells","volume":"95","author":"Joyce","year":"2012","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.03.008_bib97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.mcna.2021.01.004","article-title":"Glaucoma","volume":"105","author":"Kang","year":"2021","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.oret.2019.09.017","article-title":"Surgical Method for Implantation of a Biosynthetic Retinal Pigment Epithelium Monolayer for Geographic Atrophy: Experience from a Phase 1\/2a Study","volume":"4","author":"Kashani","year":"2020","journal-title":"Ophthalmol Retin"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.008_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9113524","article-title":"Effects of netarsudil on actin-driven cellular functions in normal and glaucomatous trabecular meshwork cells: A live imaging study","volume":"9","author":"Keller","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib102","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-018-0126-8","article-title":"Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma","volume":"50","author":"Khawaja","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.survophthal.2025.03.008_bib103","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 Study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.008_bib104","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2011.05.046","article-title":"Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment","volume":"58","author":"Kikuchi","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.survophthal.2025.03.008_bib105","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.yexcr.2006.08.009","article-title":"Quantitative assessment of local collagen matrix remodeling in 3-D culture: the role of Rho kinase","volume":"312","author":"Kim","year":"2006","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib106","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.exer.2007.07.008","article-title":"Microtubule regulation of corneal fibroblast morphology and mechanical activity in 3-D culture","volume":"85","author":"Kim","year":"2007","journal-title":"Exp Eye Res"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.008_bib107","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMoa1712770","article-title":"Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy","volume":"378","author":"Kinoshita","year":"2018","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1016\/j.survophthal.2025.03.008_bib108","doi-asserted-by":"crossref","first-page":"17504","DOI":"10.1073\/pnas.0804054105","article-title":"Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target","volume":"105","author":"Kita","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/db06-0581","article-title":"Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor","volume":"56","author":"Kita","year":"2007","journal-title":"Diabetes"},{"issue":"26","key":"10.1016\/j.survophthal.2025.03.008_bib110","article-title":"Effects of rho-associated protein kinase inhibitor Y-27632 on scarring formation after glaucoma filtration surgery","volume":"28","author":"Ko","year":"2017","journal-title":"Mol Biol Cell Conf"},{"key":"10.1016\/j.survophthal.2025.03.008_bib111","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exer.2014.05.006","article-title":"Corneal epithelial and neuronal interactions: role in wound healing","volume":"125","author":"Kowtharapu","year":"2014","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib112","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00599.2020","article-title":"TRPV4-Rho signaling drives cytoskeletal and focal adhesion remodeling in trabecular meshwork cells","volume":"320","author":"Lakk","year":"2021","journal-title":"Am J Physiol - Cell Physiol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081105","article-title":"Evaluation of an intravitreal rho-associated kinase inhibitor depot formulation in a rat model of diabetic retinopathy","volume":"13","author":"Lebon","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib114","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jcp.21424","article-title":"Rho plays a key role in TGF-beta1-induced cytoskeletal rearrangement in human retinal pigment epithelium","volume":"216","author":"Lee","year":"2008","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","article-title":"Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension","volume":"100","author":"Lewis","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib116","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/glia.22825","article-title":"An energy theory of glaucoma","volume":"63","author":"Li","year":"2015","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/atm.2020.03.86","article-title":"RPE epithelial-mesenchymal transition plays a critical role in the pathogenesis of proliferative vitreoretinopathy","volume":"8","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib118","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/jop.2022.0069","article-title":"Phase 2, Randomized, open-label parallel-group study of two dosing regimens of netarsudil for the treatment of corneal edema due to fuchs corneal dystrophy","volume":"38","author":"Lindstrom","year":"2022","journal-title":"J Ocul Pharm Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib119","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1167\/iovs.07-0451","article-title":"Induction by latanoprost of collagen gel contraction mediated by human tenon fibroblasts: role of intracellular signaling molecules","volume":"49","author":"Liu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.008_bib120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","article-title":"Progress in corneal wound healing","volume":"49","author":"Ljubimov","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib121","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/1475636021000005659","article-title":"Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885","volume":"17","author":"Loge","year":"2002","journal-title":"J Enzym Inhib Med Chem"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib122","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/ICO.0000000000001883","article-title":"Use of topical rho kinase inhibitors in the treatment of fuchs dystrophy after descemet stripping only","volume":"38","author":"Macsai","year":"2019","journal-title":"Cornea"},{"issue":"13","key":"10.1016\/j.survophthal.2025.03.008_bib123","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/hc1002.105938","article-title":"Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina","volume":"105","author":"Masumoto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.survophthal.2025.03.008_bib124","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jtos.2021.08.011","article-title":"The effect of Rho Kinase inhibition on corneal nerve regeneration in vitro and in vivo","volume":"22","author":"Mertsch","year":"2021","journal-title":"Ocul Surf"},{"issue":"23","key":"10.1016\/j.survophthal.2025.03.008_bib125","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1074\/jbc.M510934200","article-title":"Myelin-associated glycoprotein inhibits microtubule assembly by a Rho-kinase-dependent mechanism","volume":"281","author":"Mimura","year":"2006","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib126","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1038\/s41598-019-40194-5","article-title":"Effect of ripasudil on diabetic macular edema","volume":"9","author":"Minami","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib127","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.exer.2005.09.024","article-title":"Critical role of the Rho-kinase pathway in TGF-beta2-dependent collagen gel contraction by retinal pigment epithelial cells","volume":"82","author":"Miura","year":"2006","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010075","article-title":"Safety and efficacy of the rho-kinase inhibitor (ripasudil) in bleb needling after trabeculectomy: a prospective multicenter study","volume":"13","author":"Mizuno","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib129","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/ICO.0000000000002437","article-title":"Descemet stripping only supplemented with topical ripasudil for fuchs endothelial dystrophy 12-month outcomes of the sydney eye hospital study","volume":"40","author":"Moloney","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2025.03.008_bib130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-030-21735-8_14","article-title":"Role of Bioactive Sphingolipids in Inflammation and Eye Diseases","volume":"1161","author":"Mondal","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib131","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1096\/fj.15-279802","article-title":"Cathepsin D: an Mvarphi-derived factor mediating increased endothelial cell permeability with implications for alteration of the blood-retinal barrier in diabetic retinopathy","volume":"30","author":"Monickaraj","year":"2016","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib132","first-page":"101","article-title":"Use of rho kinase inhibitors in ophthalmology: a review of the literature","volume":"7","author":"Moshirfar","year":"2018","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib133","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","article-title":"Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology","volume":"257","author":"Moura-Coelho","year":"2019","journal-title":"Graefe'S Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib134","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","article-title":"Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology","volume":"257","author":"Moura-Coelho","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.exer.2015.07.008","article-title":"Effect of intravitreal Rho kinase inhibitor ripasudil (K-115) on feline retinal microcirculation","volume":"139","author":"Nakabayashi","year":"2015","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib136","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib137","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/eye.2009.325","article-title":"Surgical management of the late complications of proliferative diabetic retinopathy","volume":"24","author":"Newman","year":"2010","journal-title":"Eye (Lond)"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib138","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/1566524018666180316150936","article-title":"ROCK Inhibitor Y-27632 promotes human retinal pigment epithelium survival by altering cellular biomechanical properties","volume":"17","author":"Ni","year":"2017","journal-title":"Curr Mol Med"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib139","first-page":"337","article-title":"Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study","volume":"8","author":"Nourinia","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib140","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2017-310378","article-title":"ROCK inhibitors for the treatment of ocular diseases","volume":"102","author":"Nourinia","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib141","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10384-017-0524-y","article-title":"Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits","volume":"61","author":"Ohta","year":"2017","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib142","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1167\/iovs.15-17595","article-title":"Effect of the rho kinase inhibitor Y-27632 on corneal endothelial wound healing","volume":"56","author":"Okumura","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib143","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2174\/1381612822666161205110027","article-title":"The role of rho kinase inhibitors in corneal endothelial dysfunction","volume":"23","author":"Okumura","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1167\/iovs.13-12225","article-title":"Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing","volume":"55","author":"Okumura","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib145","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1167\/iovs.15-18586","article-title":"Effect of the rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing","volume":"57","author":"Okumura","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"38","key":"10.1016\/j.survophthal.2025.03.008_bib146","doi-asserted-by":"crossref","first-page":"13876","DOI":"10.1073\/pnas.1410602111","article-title":"Altered mechanobiology of Schlemm's canal endothelial cells in glaucoma","volume":"111","author":"Overby","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.survophthal.2025.03.008_bib147","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib148","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5966\/sctm.2014-0179","article-title":"Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel, synthetic substrate","volume":"4","author":"Pennington","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.survophthal.2025.03.008_bib149","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"SK. Aqueous humor dynamics: a review","volume":"4","author":"Picciani","year":"2010","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.survophthal.2025.03.008_bib150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2021.03.006","article-title":"Randomized, double-masked, pilot study of netarsudil 0.02% ophthalmic solution for treatment of corneal edema in fuchs dystrophy","volume":"227","author":"Price","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib151","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"Broman AT. The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib152","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00063030-200721030-00004","article-title":"Rho GTPase\/Rho kinase inhibition as a novel target for the treatment of glaucoma","volume":"21","author":"Rao","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.survophthal.2025.03.008_bib153","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib154","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41433-023-02667-w","article-title":"Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients","volume":"38","author":"Rennie","year":"2024","journal-title":"Eye (Lond)"},{"issue":"5557","key":"10.1016\/j.survophthal.2025.03.008_bib155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1066901","article-title":"Adult-onset primary open-angle glaucoma caused by mutations in optineurin","volume":"295","author":"Rezaie","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.survophthal.2025.03.008_bib156","unstructured":"Ritch R. A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma (ROCK) Clinicaltrials.gov2018 [Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT01936389?term=rho+kinase+inhibitor&cond=Ocular+Hypertension&draw=\u20092&rank=\u20091."},{"key":"10.1016\/j.survophthal.2025.03.008_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109745","article-title":"Inhibition of Rho kinase (ROCK) impairs cytoskeletal contractility in human Muller glial cells without effects on cell viability, migration, and extracellular matrix production","volume":"238","author":"Roda","year":"2024","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib158","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on Retinal Vein Occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac J Ophthalmol (Philos"},{"key":"10.1016\/j.survophthal.2025.03.008_bib159","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic Macular Edema Pathophysiology: Vasogenic Versus Inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J Diabetes Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.exer.2004.12.013","article-title":"Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork","volume":"80","author":"Rosenthal","year":"2005","journal-title":"Exp Eye Res"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib161","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib162","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1038\/s41598-017-07329-y","article-title":"ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: contribution to diabetic retinopathy","volume":"7","author":"Rothschild","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib163","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1167\/iovs.06-0299","article-title":"Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis","volume":"47","author":"Rudnicka","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib164","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9394(14)75004-4","article-title":"The pathophysiology of proliferative vitreoretinopathy in its management","volume":"100","author":"Ryan","year":"1985","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","article-title":"Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes","volume":"18","author":"Saad","year":"2020","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2021.101559","article-title":"Keratoconus: an updated review","volume":"45","author":"Santodomingo-Rubido","year":"2022","journal-title":"Cont Lens Anterior Eye"},{"key":"10.1016\/j.survophthal.2025.03.008_bib167","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"9967","key":"10.1016\/j.survophthal.2025.03.008_bib168","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1\/2 studies","volume":"385","author":"Schwartz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.03.008_bib169","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib170","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/09273948.2020.1870148","article-title":"The role of inflammatory cytokines in neovascularization of chemical ocular injury","volume":"30","author":"Shahriary","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2025.03.008_bib171","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2016.07.006","article-title":"Topical administration of a Rock\/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury","volume":"158","author":"Shaw","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.03.008_bib172","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2016.07.006","article-title":"Topical administration of a Rock\/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury","volume":"158","author":"Shaw","year":"2017","journal-title":"Exp Eye Res"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib173","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1167\/iovs.13-11684","article-title":"Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-beta1\/ERK pathways regulation","volume":"54","author":"Shin","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib174","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/ICO.0000000000000493","article-title":"Inhibition of Rho-Associated Kinase Prevents Pathological Wound Healing and Neovascularization After Corneal Trauma","volume":"34","author":"Sijnave","year":"2015","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0974-620X.116624","article-title":"Ocular chemical injuries and their management","volume":"6","author":"Singh","year":"2013","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib176","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study","volume":"226","author":"Sit","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib177","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2147\/OPTH.S399981","article-title":"Characteristics and treatment patterns of patients with diabetic macular edema non-responsive to anti-vascular endothelial growth factor treatment in Ontario, Canada","volume":"17","author":"Somani","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib178","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1152\/physrev.00023.2003","article-title":"Ca2+\u2009sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase","volume":"83","author":"Somlyo","year":"2003","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib179","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00417-023-06192-0","article-title":"MERCURY-3: a randomized comparison of netarsudil\/latanoprost and bimatoprost\/timolol in open-angle glaucoma and ocular hypertension","volume":"262","author":"Stalmans","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"27","key":"10.1016\/j.survophthal.2025.03.008_bib180","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2174\/1381612043383124","article-title":"Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy","volume":"10","author":"Stitt","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib181","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1167\/iovs.10-5265","article-title":"Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits","volume":"52","author":"Sugiyama","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib182","first-page":"1266","article-title":"A Rho-associated protein kinase: differentially distributed in limbal and corneal epithelia","volume":"39","author":"SundarRaj","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib183","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/ICU.0000000000000748","article-title":"Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease","volume":"32","author":"Syed","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib184","first-page":"133","article-title":"Leibowitz HM. Hydrophilic contact lenses in corneal disease","volume":"86","author":"Takahashi","year":"1971","journal-title":"3 Top hypertonic Saline Ther bullous keratopathy Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib185","first-page":"565","article-title":"Role of transforming growth factor Beta in corneal function, biology and pathology","volume":"10","author":"Tandon","year":"2010","journal-title":"Curr Mol Med"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib186","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: A report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib187","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24\u2009h in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib188","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.008_bib189","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib190","article-title":"Rho kinase inhibitors as a neuroprotective pharmacological intervention for the treatment of glaucoma","volume":"14","author":"Thomas","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib191","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/eop.12.12","article-title":"Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications","volume":"7","author":"Tian","year":"2012","journal-title":"Expert Rev Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib192","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/02713683.2011.599106","article-title":"Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats","volume":"36","author":"Tokushige","year":"2011","journal-title":"Curr Eye Res"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.008_bib193","doi-asserted-by":"crossref","DOI":"10.3390\/cells12111485","article-title":"Injury to cone synapses by retinal detachment: differences from rod synapses and protection by ROCK inhibition","volume":"12","author":"Townes-Anderson","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib194","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.6.3.22","article-title":"Fasudil, a clinically used ROCK inhibitor, stabilizes rod photoreceptor synapses after retinal detachment","volume":"6","author":"Townes-Anderson","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib195","unstructured":"Trevino R. Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation Clinicaltrials.gov2020 [Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04234932?term=rho+kinase+inhibitor&cond=Ocular+Hypertension&draw=\u20092&rank=\u20095."},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib196","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1089\/jop.2019.0089","article-title":"One-year efficacy and safety assessment of ripasudil, a rho kinase inhibitor, in an addition to or replacing existing treatment regimens: a retrospective study","volume":"36","author":"Tsukahara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib197","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1167\/iovs.08-1973","article-title":"Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina","volume":"50","author":"Tura","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6654","key":"10.1016\/j.survophthal.2025.03.008_bib198","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2025.03.008_bib199","unstructured":"University S. Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma (NTG) Clinicaltrials.gov2021 [Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04981886?term=rho+kinase+inhibitor&cond=Ocular+Hypertension&draw=\u20092&rank=\u20096."},{"key":"10.1016\/j.survophthal.2025.03.008_bib200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","article-title":"Towards axonal regeneration and neuroprotection in glaucoma: rho kinase inhibitors as promising therapeutics","volume":"131","author":"Van de Velde","year":"2015","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.survophthal.2025.03.008_bib201","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.2147\/OPTH.S337105","article-title":"Effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy","volume":"15","author":"Villegas","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib202","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1076\/ceyr.22.6.470.5489","article-title":"Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase","volume":"22","author":"Waki","year":"2001","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.008_bib203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","article-title":"Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 mercury-2 study","volume":"2","author":"Walters","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib204","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1167\/iovs.18-26077","article-title":"Actin dynamics, regulated by RhoA-LIMK-Cofilin signaling, mediates rod photoreceptor axonal retraction after retinal injury","volume":"60","author":"Wang","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.008_bib205","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/j.1582-4934.2012.01538.x","article-title":"Up-regulation of BMP-2 antagonizes TGF-beta1\/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1\/Smad6 complex","volume":"16","author":"Wang","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"13","key":"10.1016\/j.survophthal.2025.03.008_bib206","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1167\/iovs.15-17278","article-title":"LIM kinase, a newly identified regulator of presynaptic remodeling by rod photoreceptors after injury","volume":"56","author":"Wang","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.008_bib207","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1167\/iovs.16-19447","article-title":"RhoA signaling and synaptic damage occur within hours in a live pig model of CNS injury, retinal detachment","volume":"57","author":"Wang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.008_bib208","article-title":"Crosslinking-induced corneal endothelium dysfunction and its protection by topical ripasudil treatment","volume":"2022","author":"Wang","year":"2022","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.008_bib209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.17-22259","article-title":"Pharmacology of corticosteroids for diabetic macular edema","volume":"59","author":"Whitcup","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1350-9462(99)00015-4","article-title":"The regulation of trabecular meshwork and ciliary muscle contractility","volume":"19","author":"Wiederholt","year":"2000","journal-title":"Prog Retin Eye Res"},{"issue":"R1","key":"10.1016\/j.survophthal.2025.03.008_bib211","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddx184","article-title":"Genetics of glaucoma","volume":"26","author":"Wiggs","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.008_bib212","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3727\/096368914X685069","article-title":"Ex vivo propagation of human corneal stromal \"activated keratocytes\" for tissue engineering","volume":"24","author":"Yam","year":"2015","journal-title":"Cell Transpl"},{"key":"10.1016\/j.survophthal.2025.03.008_bib213","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8543592","article-title":"Rho-Kinase\/ROCK as a Potential Drug Target for Vitreoretinal Diseases","volume":"2017","author":"Yamaguchi","year":"2017","journal-title":"J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.008_bib214","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1167\/iovs.13-13842","article-title":"The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma","volume":"55","author":"Yamamoto","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.008_bib215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/ml1000382","article-title":"Discovery of potent and selective urea-based rock inhibitors and their effects on intraocular pressure in rats","volume":"1","author":"Yin","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib216","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1167\/iovs.07-1122","article-title":"Role of small GTPase Rho in regulating corneal epithelial wound healing","volume":"49","author":"Yin","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib217","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10384-007-0471-0","article-title":"Involvement of the Rho\/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina","volume":"51","author":"Yokota","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"2-3","key":"10.1016\/j.survophthal.2025.03.008_bib218","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.brainresbull.2009.08.024","article-title":"Growth factors and corneal epithelial wound healing","volume":"81","author":"Yu","year":"2010","journal-title":"Brain Res Bull"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.008_bib219","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/03007995.2021.1901222","article-title":"A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting","volume":"37","author":"Zaman","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.008_bib220","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2015.01.050","article-title":"ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration","volume":"10","author":"Zandi","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.survophthal.2025.03.008_bib221","first-page":"688","article-title":"Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice","volume":"21","author":"Zeng","year":"2015","journal-title":"Mol Vis"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.008_bib222","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/1673-5374.228761","article-title":"The ROCK pathway inhibitor Y-27632 mitigates hypoxia and oxidative stress-induced injury to retinal Muller cells","volume":"13","author":"Zhang","year":"2018","journal-title":"Neural Regen Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.008_bib223","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1167\/iovs.02-0808","article-title":"Involvement of rho-kinase pathway in contractile activity of rabbit RPE cells in vivo and in vitro","volume":"45","author":"Zheng","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572500058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003962572500058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:29:50Z","timestamp":1762219790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003962572500058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":223,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S003962572500058X"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.03.008","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the potential of rho kinase inhibitors in ophthalmology: From mechanisms to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}